School of Engineering Sciences in Chemistry, Biotechnology and Health at KTH
The Science for Life Laboratory (SciLifeLab, www.scilifelab.se ) is Sweden´s national infrastructure for molecular bioscience, with a mission to support academic research and drug development. The centre combines advanced technical know-how and state-of-the-art equipment with a broad knowledge in translational medicine, e.g. through the SciLifeLab Drug Discovery & Development platform (SciLifeLab DDD, https://www.scilifelab.se/units/ddd-platform/). The SciLifeLab DDD platform is composed of several units with unique competencies related to drug discovery and development processes for both biologics and small molecules. These units are physically located in Stockholm, Uppsala, Gothenburg, and Lund and staffed by researchers employed at local universities. Typically, drug development projects run by the SciLifeLab DDD platform stem from academic basic science projects, in which opportunities to intervene with disease processes with either biologics, oligonucleotides, or small molecules have been identified and perceived to have commercial potential. A steering group prioritizes which projects receive support from the SciLifeLab DDD platform.
The Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH School) at KTH, now look to recruit a new Head of Unit for its Human Antibody Therapeutics (HAT) unit at SciLifeLab DDD in Stockholm.
The Human Antibody Therapeutics (HAT) unit at SciLifeLab DDD is an established and high-performing unit with a staff of six senior researchers, scientifically supported by three platform scientific directors (professor level). The unit has laboratories at both SciLifeLab campus in Stockholm, and at Medicon Village in Lund. The unit´s main responsibility is to drive the SciLifeLab DDD antibody drug discovery programs in collaboration with other competencies from the whole SciLifeLab DDD infrastructure (approx. 45 employees) as well as academic principal investigators (PIs). An essential component for this work is several in-house developed phage-display human antibody libraries with proven ability to deliver high-affinity binders to targets of interest for further development into therapeutic antibody candidates. The unit is also responsible for other in vitro selection-based methods such as DNA-encoded chemical libraries for the discovery of small molecule drug candidates.
As head of the human antibody therapeutics unit you will be responsible for the planning of daily activities and be accountable for project delivery on time. The unit head will be involved in the design and planning of antibody selection from large combinatorial libraries, characterization and evolution of antibody fragments, and antibody engineering, as well as to drive methodology and tools development projects.
You will find contact information to trade union representatives at KTH.se
Log into KTH’s recruitment system in order to apply to this position. You are responsible to ensure that your application is complete according to the instructions in the ad.
The application must include:
Your complete application must be received by KTH no later than the last day of application, midnight CET/CEST (Central European Time/Central European Summer Time).
The employment is valid until further notice (permanent post) according to agreement.
The employment begins with a six-month probationary period
|Type of employment||Permanent position|
|Contract type||Full time|
|First day of employment||The employment is valid until further notice (permanent post) according to agreement.|
|Number of positions||1|
|Contact||Anders Olsson, 070-5585882|
Cecilia Williams, 08 790 98 91
Per Arvidsson, 0852481398
|Last application date||15.Nov.2021 11:59 PM CET|